FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.

Source: The Rheumatologist - October 9, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: DMARDs & Immunosuppressives Drug Updates FDA polyarticular juvenile idiopathic arthritis (JIA) Tofacitinib U.S. Food and Drug Administration (FDA) Source Type: research